# Genpact Limited (G) fundamentals

Data as of 2026-11-04. NYSE, United States. Sector: Technology / IT Services. Price $40.22, market value $6.7 billion.

## Valuation
- **P/E (trailing): 12.0×** (5-yr avg 17.8×, 3-yr avg 13.1×). Genpact Limited trades at 12.0× trailing earnings, well below its own five-year average of 17.8×: cheap by its own standards. The Technology median in the September 2026 study was 32.1×. Forward P/E is 8.9×, lower than trailing, so analysts expect earnings to grow.
- **PEG: 0.91**. A PEG of 0.91 means the P/E is low relative to expected earnings growth: the market is not paying much for that growth.
- **Price / sales: 1.3×**. Each dollar of revenue is priced at 1.3×.
- **Price / book: 2.6×**. The shares trade at 2.6× book value; book value is a meaningful part of the valuation.
- **Free-cash-flow yield: 8.5%** (5-yr avg 6.9%). Free cash flow equals 8.5% of the market value, above its five-year average of 6.9%, so the shares are cheaper on cash than they have usually been. Above 5% is generally attractive.
- **Earnings yield: 8.4%**. The inverse of the P/E: 8.4% of the price is earned each year.

## Profitability
- **Gross margin: 36.5%**. Genpact Limited keeps 36.5% of revenue after the direct cost of what it sells.
- **Operating margin: 14.8%**. 14.8% of revenue is left after running the business.
- **Net margin: 10.9%**. 10.9% of each dollar of sales reaches the bottom line.
- **Return on equity: 21.7%**. 21.7% on shareholders' equity is excellent if it is not driven by leverage; sustained above 20% usually signals a competitive advantage.
- **Return on invested capital: 19.0%**. Return on all capital, debt included, is 19.0%: comfortably above what that capital costs.
- **Return on assets: 10.0%**. Each dollar of assets produces 10.0% of profit.

## Growth
- **Revenue growth (1 yr): 6.6%** (3-yr 5.1%/yr, 5-yr 6.5%/yr). Revenue grew 6.6% over the last year, against 6.5% a year compounded over five years.
- **EPS growth (1 yr): 9.8%** (3-yr 18.5%/yr, 5-yr 14.8%/yr). Earnings per share rose 9.8%, roughly in step with revenue.
- **Free-cash-flow growth (3 yr): 23.2%/yr**. Free cash flow has compounded at 23.2% a year over three years, keeping pace with earnings: the growth is real cash.

## Financial health
- **Debt to equity: 0.60**. Debt is 0.60 times equity, moderate leverage.
- **Current ratio: 1.66** (quick 1.66). Current assets cover the next year's liabilities 1.66 times.
- **Altman Z-score: 3.35**. A Z-score of 3.35 places the company in the safe zone for bankruptcy risk.
- **Piotroski F-score: 6/9**. 6 of 9 checks pass: mixed.

## Dividends
- **Dividend yield: 1.86%** ($0.71 per share, trailing). Genpact Limited yields 1.86%, a modest yield more typical of a growth-oriented payer.
- **Payout ratio: 21%** (21% of free cash flow). 21% of earnings goes out as dividends, leaving room to keep raising it.
- **Consecutive years of increases: 9**. 9 straight years of increases.
- **Dividend growth (5 yr): 11.6%/yr** (1-yr 11.1%). The dividend has compounded at 11.6% a year over five years, doubling roughly every 6 years at that pace.

## Analyst view
- **Analyst consensus: buy** (11 analysts). 11 analysts cover Genpact Limited; the consensus is buy, with an average price target of $42.91 (+7% from the current price). Analyst opinion is shown for context; it is not part of the Fundamental Score.

## Price and momentum
- **Total return (1 yr): 7.4%** (YTD -12.5%, 3-mo 15.2%). The shares are up 7.4% over twelve months including dividends.
- **From 52-week high: -17.3%** (49.8% above the low). Trading 17% below its 52-week high.
- **200-day average: above**. The price sits above its 200-day moving average, the usual definition of an uptrend.
- **RSI (14-day): 66**. An RSI of 66 is neutral.
- **Beta (1 yr): 0.11** (volatility 41%). Beta of 0.11 against the S&P 500: the shares move much less than the market.

Live score and charts: https://foliofundamentals.com/analyzer?s=G · Page: https://foliofundamentals.com/stocks/g

Not investment advice.